Westpac Banking Corp’s Sarepta Therapeutics SRPT Stock Holding History

Westpac Banking Corp’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$129K	Hold	7,173	–	–	0.01%	419
2026 Q1	$156K	Hold	7,173	–	–	0.01%	386
2025 Q4	$154K	Buy	+7,173	New	+$151K	0.01%	375
2021 Q2	–	Sell	-6,319	Closed	-$471K	–	867
2021 Q1	$471K	Hold	6,319	–	–	0.01%	772
2020 Q4	$1.08M	Hold	6,319	–	–	0.01%	710
2020 Q3	$887K	Hold	6,319	–	–	0.01%	691
2020 Q2	$1.01M	Hold	6,319	–	–	0.02%	632
2020 Q1	$618K	Hold	6,319	–	–	0.01%	690
2019 Q4	$815K	Hold	6,319	–	–	0.01%	727
2019 Q3	$476K	Buy	+6,319	New	+$746K	0.01%	794

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Westpac Banking Corp's SRPT Position: Q2 2026 in Review

Westpac Banking Corp held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 7,173 shares worth $129K. The position accounts for 0.01% of the portfolio, ranked #419.

Westpac Banking Corp first reported a position in SRPT in Q3 2019 and has held it in 10 quarters since. The position peaked at $1.08M in Q4 2020. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Westpac Banking Corp held 7,173 shares of Sarepta Therapeutics worth $129K as of Q2 2026.
Westpac Banking Corp left its Sarepta Therapeutics share count unchanged in Q2 2026.
Sarepta Therapeutics made up 0.01% of Westpac Banking Corp's portfolio in Q2 2026, its #419 holding.
Westpac Banking Corp first reported a position in Sarepta Therapeutics in Q3 2019 and has held it in 10 quarters since.
Westpac Banking Corp's Sarepta Therapeutics position peaked at $1.08M in Q4 2020.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Westpac Banking Corp's 13F filing for Q2 2026, filed 12 Aug 2026.